Literature DB >> 2550359

Monoclonal antibodies M340 and UJ181.4 recognize antigens associated with primitive neuroectodermal tumours/tissues.

S Bourne1, L Pemberton, R Moseley, L S Lashford, H B Coakham, J T Kemshead.   

Abstract

Monoclonal antibodies UJ181.4 and M340 were raised from separate fusions using either human foetal brain or medulloblastoma tissue as immunogens. The antibodies are both of IgG isotype and bind to their target antigens with affinities in excess of 10(-9) M. Both monoclonal antibodies have been shown to bind to primitive neuroectodermal tumours and human foetal brain. Expression of the two antigens is developmentally regulated as no binding is detected on adult brain as determined by a variety of indirect binding assays. The two monoclonal antibodies can be clearly distinguished by their migration in a pH gradient (isoelectric focussing gels). UJ181.4 and M340 clearly recognize two different epitopes, as it is not possible to block the binding of one antibody with an excess of the other. In addition, careful study of the binding profiles of the two reagents suggest that they recognize two distinct antigens, although these have not been biochemically characterized. The reagents have proved particularly useful in both the differential diagnosis of the small round cell tumours of childhood and anaplastic brain tumours. In addition, they have formed part of a panel of reagents used for the immunomagnetic depletion of neuroblasts from bone marrow and have been used for targeting radionuclides to tumour cells in the intrathecal compartment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550359     DOI: 10.1089/hyb.1989.8.415

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  5 in total

1.  Dosimetry of intrathecal iodine131 monoclonal antibody in cases of neoplastic meningitis.

Authors:  R B Richardson; J T Kemshead; A G Davies; G E Staddon; P C Jackson; H B Coakham; L S Lashford
Journal:  Eur J Nucl Med       Date:  1990

2.  Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.

Authors:  D K Strickland; G Vaidyanathan; H S Friedman; M R Zalutsky
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

3.  Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients.

Authors:  H B Coakham; J T Kemshead
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

4.  Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.

Authors:  R P Moseley; A G Davies; R B Richardson; M Zalutsky; S Carrell; J Fabre; N Slack; J Bullimore; B Pizer; V Papanastassiou
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

5.  Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.

Authors:  J T Kemshead; K Hopkins; B Pizer; V Papanastassiou; H Coakham; J Bullimore; C Chandler
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.